• B Riley has initiated Viking Therapeutics at buy saying that the company lead obesity treatment, VK2735, could have "long-term disruptive potential."
• The investment bank has a $109 price target (~111% upside based on Nov. 21 close).
• Analyst Mayank Mamtani said that VK2735 could set itself apart from existing weight loss drugs as it is a "GLP1/GIP agonist being developed
  for an induction (injection [SQ] weekly) and maintenance (oral [PO] or SQ monthly) paradigm."
• Despite VK2735 demonstrating strong clinical results so far, the stock is down ~50% off its 52-week high, he noted, adding that upcoming "additional visibility into manufacturing capacity and competitive positioning [could] unlock significant value through YE 2025E."
• And while Viking's drug is competing against other candidates, such as Novo Nordisk's (NVO) CagriSema, Amgen's (AMGN) MariTide, and Roche's (OTCQX:RHHBY) GYM329, data updates from these programs "represent an opportunity, in our opinion, for VK2735's unique positioning to further stand out while bringing into focus the broader portfolio optionality."

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。